New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
09:36 EDTAEGREMA rejection bodes well for Aegerion, says Deutsche Bank
Deutsche Bank said the European Medicines Agency's rejection of the re-examination request for Mipomersen in Homozygous Familial Hypercholesterolemia bodes well for the approval of Aegerion's Lomitapide in Europe. The firm reiterates a Buy rating on Aegerion with a $41 price target.
News For AEGR From The Last 14 Days
Check below for free stories on AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 9, 2014
08:08 EDTAEGRAegerion initiates Phase 3 clinical trial for lomitapide in Japan
Subscribe for More Information
April 8, 2014
11:03 EDTAEGRPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use